1.. Introduction {#s1}
================

Venous thromboembolism (VTE) is a potential life-threatening complication that can arise during hospitalization for surgery or for medical illness \[[@B1],[@B2]\]. The vast majority (80%) of hospitalized patients with symptomatic VTE are nonsurgical patients \[[@B3]--[@B5]\]. Furthermore, 70% to 80% of cases of fatal pulmonary embolism in the hospital occur in medical patients \[[@B6]--[@B8]\].

The worldwide incidence of VTE is difficult to quantify, as clinical symptoms can be nonspecific and screening techniques can fail to properly assess nonsymptomatic patients. Even so, it is thought that at least 5--15% of hospitalized medical patients will develop VTE, making it the most common preventable cause of in-hospital death \[[@B1],[@B2]\].

The incidence of hospital-acquired deep venous thrombosis with confirmed objective diagnosis is 10--40% among surgical and medical patients. However, this incidence rises to 40--60% after major orthopedic surgery \[[@B7]--[@B9]\].

The American College of Chest Physicians (ACCP) released the latest updated guidelines in 2012, which defined the patient's risk and recommendation of prophylaxis accordingly. Patients who fall into the high-risk group are estimated to have between 40% and 80% risk of developing VTE if no prophylaxis is provided \[[@B10]\]. Recommended prophylaxis measures include: treatment with low molecular weight heparin (LMWH), low-dose unfractionated heparin (UFH), or fondaparinux for patients undergoing major surgery. Mechanical methods of prophylaxis are urged for patients with a high bleeding risk \[[@B10]\]. Unfortunately, numerous international and national studies suggest that there is gap between guideline and practice. The ENDORSE study found that more than 50% of hospitalized patients should have received VTE thromboprophylaxis, but in fact only half of them actually received it \[[@B11]\]. The International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) registry, an ongoing international registry of prophylaxis patterns in the medically ill, has shown that only 60% of potentially at risk patients are receiving any prophylaxis \[[@B12]\]. We conducted a retrospective study in order to determine the prevalence of the high-risk medical and surgical patient in our hospital and to evaluate the utilization of prophylaxis in this patient group. The primary endpoint was the rate of appropriate thromboprophylaxis.

2.. Methods {#s2}
===========

2.1.. Study design {#s2.1}
------------------

We conducted a retrospective cohort study at King Fahad Hospital (Madinah, Saudi Arabia), a tertiary referral hospital with 400 beds. It manages all type of surgical (general surgery, orthopedic surgery, vascular surgery, and neurosurgical patients) and medical patients excluding obstetrics and gynecology. We reviewed all patients admitted to the hospital including critical care department between July 2015 and September 2015. The study protocol was approved by the Ethics Committee.

2.2.. Patients {#s2.2}
--------------

Inclusion criteria included: age 14 years and older; admitted to the hospital with medical and surgical problems for more than 3 days. Exclusion criteria included any patients on anticoagulation for therapeutic purpose or missing chart.

2.3.. Data collection {#s2.3}
---------------------

The following data were collected from the medical charts: age, sex, and risk factors for VTE. We also included surgical or medical patients risk assessment and VTE prophylaxis given and compliance as per ACCP guidelines. We used the Caprini score for surgical patients and Padua score for medical patients.

2.4.. Statistical analysis {#s2.4}
--------------------------

Continuous variables were described as mean ± standard deviation for normally distributed variables and categorical variables as percentages. χ^2^ test was used to compare between categorical variables.

3.. Results {#s3}
===========

A total of 460 patients admitted to King Fahad Hospital from July 1, 2015 to September 30, 2015 were initially screened; 46 patients were excluded for receiving therapeutic anticoagulation. Overall, 414 patients were included in the study.

The mean age of patients was 47.74 ± 20.4 years, and 208 (50.2%) were female. Thirty-one (7.5%) patients were younger than 20 years. Their baseline characteristics are shown in [Table 1](#T1){ref-type="table"}.

###### 

Patients' baseline characteristics.

                              *N* (%)/mean
  --------------------------- --------------
  Mean age (y)                47.74 ± 20.4
  Sex                         
  Male                        206 (49.8%)
  Female                      208 (50.2%)
  Risk factor                 
  DM                          143 (34.5%)
  HTN                         148 (35.7%)
  Stroke                      60 (14.5%)
  Heart failure               58 (14.0%)
  Smoking                     65 (15.7%)
  Venous catheter             109 (26.3%)
  Ischemic heart disease      146 (35.3%)
  COPD                        57 (13.8%)
  Renal failure               70 (16.9%)
  Endocrine                   132 (31.9%)
  Connective tissue disease   22 (5.3%)
  Surgery                     131 (31.6%)
  Immobilized                 163 (39.4%)
  Multiple trauma             81 (19.6%)
  Obesity                     137 (33.1%)

COPD =; DM = diabetes mellitus; HTN =.

A total of 210 (50.7%) of patients were identified as surgery patients and 204 (49.3%) were medical patients [Table 2](#T2){ref-type="table"}.

###### 

Distribution of patients according to risk stratification.

  ----------------------------------------------------------------------
  Risk classification   Surgical, 210 (50.7%)\   Medical, 204 (49.3%)\
                        *N* (%)                  *N* (%)
  --------------------- ------------------------ -----------------------
  High                  173(82.3%)               118 (58%)

  Moderate              24(11.4%)                49 (24%)

  Low                   13 (6.1%)                37 (18.1)
  ----------------------------------------------------------------------

As per ACCP risk categorization, 173 (82.3%) surgical patients were classified as high risk and 24 (11.4%) as moderate risk.

A variety of prophylaxis methods were used including pharmacological "UFH" or "LMWH" (45.6%), intermittent pneumatic compression devices (2.4%), combination of intermittent pneumatic compression devices with pharmacological (6.8%), and no therapy (45.1%). These results are summarized in [Fig. 1](#F1){ref-type="fig"}.

![Prophylaxis methods used in the study group.](JEGH-7-4-295-g001){#F1}

According to the ACCP criteria, 375 (90.5%) among surgical and medical patients were at risk of VTE and qualified for prophylaxis. Although 227 (60.5%) received some form of prophylaxis, only 144 (38.4%) of them received ACCP-recommended VTE prophylaxis.

More medical patients (112; 55%) received ACCP-recommended prophylaxis compared with surgical patients 32 (15%; *p* \> 0.0001) ([Fig. 2](#F2){ref-type="fig"}). Furthermore, patients in the high-risk group received prophylaxis more than patients in moderate- and lower-risks groups did. Indeed, 102 (35%) of high-risk patients and 46% of moderate-risk patients received no therapy ([Fig. 3](#F3){ref-type="fig"}).
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4.. Discussion {#s4}
==============

This is the first study conducted in our institute to evaluate the prevalence of at-risk medical and surgical patients. Our finding that 90.5% of our patients are at risk for VTE is consistent with the Canadian CURVE study and other studies, where 78--90% of all hospitalized patient groups had at least one major risk factor for VTE \[[@B9],[@B13],[@B14]\].

In our study, we found that only 38.4% of the patients who were eligible for prophylactic antithrombotic therapy actually received it. This is very closely similar to the finding of the national AVAIL ME study, which included 200 patients from Saudi Arabia, and found VTE prophylaxis and guideline applications ranging from 24% to 84% among different subgroups \[[@B15]\].

Overall, significantly more medical patients in our study received prophylactic antithrombotic therapy compared with surgical patients (*p* \> 0.0001; 55% vs. 15%, respectively).

The multinational IMPROVE study \[[@B12]\] showed that only 60% of medical patients who are eligible for prophylactic antithrombotic therapy actually received it. This is almost similar to the 55% rate among the medical patients in our study.

Our medical patients received prophylaxis at a higher rate compared with the patients in the Canadian CURVE study, which showed that 90% of acutely ill medical patients had an indication for thromboprophylaxis; however, only 16% received appropriate prophylaxis \[[@B15]\].

The surgical patients in our study received prophylactic antithrombotic therapy at a significantly lower rate (15%) than the surgical patients in a similar local study from Jeddah (44.1%) \[[@B16]\].

Although our figures for thromboprophylaxis are, in general, lower than the reported numbers in the literature outside the Middle East region, the low incidence stays in accordance with many studies conducted in different countries, indicating the underutilization of thromboprophylaxis. Our study highlights the necessity of improving awareness regarding VTE risk and implementing the ACCP guidelines.

Finally, the retrospective data collection in a single hospital could be perceived as a methodological weakness. However, prospective patient data collection would have required informed consent at our institution. This could have affected the validity of our results by introducing potential bias, in that patients being asked to enroll in the study prospectively may have been more likely to ask their prescribing physicians about VTE prevention. This, in turn, could have led to increased prophylaxis rates that would not be an accurate reflection of real-world practice or of our intervention.

5.. Conclusion {#s5}
==============

VTE is a major public health issue \[[@B17],[@B18]\]. It is an easily preventable disease with a substantial risk of morbidity and mortality in patients hospitalized for acute medical and surgical illnesses \[[@B19],[@B20]\].

Our data show that a large proportion of hospitalized individuals---both surgical and medical---are at risk for VTE, and that recommended VTE prophylaxis is underused. Hospital-wide strategies to assess patients' VTE risk should be implemented, together with measures that ensure that at-risk patients receive the appropriate VTE prophylaxis. Among these are hospital accreditation programs that consider VTE risk assessment as one of the essential safety measures. As a result of this study, VTE risk assessment is mandatory for all patients admitted to our hospital.
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